

The May 10, 2019, article by Turner et al entitled “Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer” (J Clin Oncol [10.1200/JCO.18.00925](https://doi.org/10.1200/JCO.18.00925)) was published with an error.

Coauthor Marco Colleoni was listed with the incorrect affiliation. In the Affiliations section, the fourth affiliation note was given as: ⁴Istituto Europeo di Oncologia, Milan, Italy

It should have read as: ⁴**The Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan**

This has been corrected as of September 16, 2019. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.19.02416>

The September 20, 2019, article by Tewari et al entitled “Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma” (J Clin Oncol [10.1200/JCO.18.02303](https://doi.org/10.1200/JCO.18.02303)) was published with an error.

In the subsection entitled “Clinical experience with anti–PD-1 therapy for refractory disease,” the third sentence of the second paragraph read “Cemiplimab recently received accelerated approval for cutaneous squamous cell carcinoma,⁶⁹ a disease with a mutational burden similar to that of squamous cell

carcinoma of the cervix.” It should have read “Cemiplimab **received approval** for cutaneous squamous cell carcinoma,⁶⁹ a disease with a mutational burden similar to that of squamous cell carcinoma of the cervix.”

This has been corrected as of September 26, 2019. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.19.02423>
